Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 21 of the 21 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: There is an established association between hypertension and increased risk of poor cognitive performance and dementia including Alzheimer's disease; however, associations between antihypertensive medications (AHMs) and dementia risk are less consistent. An increased interest in AHM has resulted in expanding publications; however, none of the recent reviews are comprehensive. Our extensive review includes 15 observational and randomized controlled trials (RCTs) published over the last 5 years, assessing the relationship between AHM and cognitive impairment. RECENT FINDINGS: All classes of AHM showed similar result patterns in human studies with the majority of study results reporting point estimates below one and only a small number of studies (N = 15) reporting statistically significant results in favor of a specific class. Only a small number of studies reported statistically significant results in favor of a specific class of AHM. Methodological limitations of the studies prevent definitive conclusions. Further work is now needed to evaluate the class of AHM and cognitive outcomes in future RCTs, with a particular focus on the drugs with the promising results in both animals and human observational studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A further complication related to pharmacological interventions is the possibility that differing trial outcomes may be influenced by their respective treatment regimens over and above any blood pressure lowering (12).”
From Oversimplification of Dementia Risk Reduction Messaging Is a Threat to Knowledge Translation in Dementia Prevention Research (2018) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441
The age-dependent relation of blood pressure to cognitive function and dementia
Qiu, C., Winblad, B., & Fratiglioni, L. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70141-1 · Cited by 1,138
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70250-7 · Cited by 216
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study
Yasar, S., Xia, J., Yao, W., Furberg, C. D., Xue, Q.-L., Mercado, C. I., Fitzpatrick, A. L., Fried, L. P., Kawas, C. H., Sink, K. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a35228 · Cited by 214
Self-citationDavies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110347 · Cited by 212
Shah, K. R., Qureshi, S. U., Johnson, M. L., Parikh, N. M., Schulz, P. E., & Kunik, M. E. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.11.001 · Cited by 140
Fournier, A., Oprisiu-Fournier, R., Serot, J.-M., Godefroy, O., Achard, J.-M., Faure, S., Mazouz, H., Temmar, M., Albu, A., Bordet, R., et al. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.89 · Cited by 129
Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia Aging Study
Gelber, R. P., Ross, G. W., Petrovitch, H., Masaki, K. H., Launer, L. J., & White, L. R. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a351d4 · Cited by 116
Long-Term Effects of Secondary Prevention on Cognitive Function in Stroke Patients
Douiri, A., McKevitt, C., Emmett, E. S., Rudd, A. G., & Wolfe, C. D. A. (2013) · Circulation · doi:10.1161/circulationaha.113.002236 · Cited by 92
Cited by
Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis
Peters, R., Yasar, S., Anderson, C. S., Andrews, S., Antikainen, R., Arima, H., Beckett, N., Beer, J. C., Bertens, A. S., Booth, A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000008732 · Cited by 153
Self-citationImmunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 93
van Dalen, J. W., Marcum, Z. A., Gray, S. L., Barthold, D., Moll van Charante, E. P., van Gool, W. A., Crane, P. K., Larson, E. B., & Richard, E. (2021) · Neurology · doi:10.1212/wnl.0000000000010996 · Cited by 52
Yang, W., Luo, H., Ma, Y., Si, S.-C., & Zhao, H. (2021) · Aging and Disease · doi:10.14336/ad.2020.1111 · Cited by 49
Accelerated DNA methylation age and the use of antihypertensive medication among older adults
Gao, X., Colicino, E., Shen, J., Just, A. C., Nwanaji‐Enwerem, J. C., Wang, C., Coull, B. A., Lin, X., Vokonas, P., Zheng, Y., et al. (2018) · Aging · doi:10.18632/aging.101626 · Cited by 32
Metadata
- Authors
- Yasar, S., Schuchman, M., Peters, J., Anstey, K. J., Carlson, M. C., & Peters, R.
- Affiliations
- Johns Hopkins University (US)
- University of Sheffield (GB)
- Australian National University (AU)
- Imperial College London (GB)
- Corresponding author
- Peters, Ruth
- Venue
- Current Hypertension Reports
- Published
- 2016-08
- Volume
- 18
- Issue
- 8
- Pages
- 67-67
- ISSN
- 1522-6417 (ISSN-L)
- 1534-3111
- PMC
- PMC4975763
- OpenAlex
- W2493560724
- Cited by
- 29
- References
- 21
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 9 · 2017: 1 · 2016: 1
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Current Hypertension Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ANU Open Research (Australian National University) (submittedVersion, cc-by)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- Imperial College London
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- antihypertensive drugs, cognitive impairment, dementia, Alzheimer's disease, hypertension, drug class effect, cognitive outcomes, randomized controlled trials, observational studies
- MeSH terms
- Alzheimer Disease, Antihypertensive Agents, Humans, Hypertension, Risk Factors, Statistics as Topic, Randomized Controlled Trials as Topic, Cognitive Dysfunction, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. https://app.cochat.ai/papers/10.1007/s11906-016-0674-1
- The paper
- Yasar, S., Schuchman, M., Peters, J., Anstey, K. J., Carlson, M. C., & Peters, R. (2016). Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. Current Hypertension Reports. https://doi.org/10.1007/s11906-016-0674-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.